Announcement on Preliminary Earnings Estimate for 2025
Filed with SSE · · 3 pages · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Acceptance of the Marketing Authorization Application for Batopoizumab Injection (BAT4406F)
- STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
- Announcement on Marketing Authorization Approval of Gotenfia (Golimumab Injection) by European Medicines Agency (EMA)
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Voluntary Disclosure of Execution of a License, Manufacturing, Supply, and Commercialization Agreement with Avalon Pharma Regarding BAT3306 (Pembrolizumab) Injection
Later from Bio-Thera Solutions
- Announcement on Voluntary Disclosure of Obtaining Marketing Authorization Approval of Usymro (Ustekinumab Injection) by UK MHRA
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT8008 Combined with BAT1006 and Trastuzumab of Advanced Solid Tumors
- Bio-Thera Solutions Announces Further Expansion of Partnership with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi® (golimumab), through Exclusive Commercialization and License Agreement in India
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Progress in Commercialization Agreement with STADA for BAT2506 (Golimumab) Injection
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT3306 Combined with BAT8008 for Treatment for Advanced Solid Tumors
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions